Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Estrogen metabolism and exposure in a genotypic-phenotypic model for breast cancer risk prediction.

Crooke PS, Justenhoven C, Brauch H; GENICA Consortium, Dawling S, Roodi N, Higginbotham KS, Plummer WD, Schuyler PA, Sanders ME, Page DL, Smith JR, Dupont WD, Parl FF.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1502-15. doi: 10.1158/1055-9965.EPI-11-0060. Epub 2011 May 24.

2.

Estrogen metabolism and breast cancer: a risk model.

Parl FF, Dawling S, Roodi N, Crooke PS.

Ann N Y Acad Sci. 2009 Feb;1155:68-75. doi: 10.1111/j.1749-6632.2008.03676.x. Review.

3.

Carcinogen-induced histone alteration in normal human mammary epithelial cells.

Bradley C, van der Meer R, Roodi N, Yan H, Chandrasekharan MB, Sun ZW, Mernaugh RL, Parl FF.

Carcinogenesis. 2007 Oct;28(10):2184-92. Epub 2007 Apr 29.

PMID:
17468514
4.

Cytochrome P450 1B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation.

Belous AR, Hachey DL, Dawling S, Roodi N, Parl FF.

Cancer Res. 2007 Jan 15;67(2):812-7.

5.

Estrogens, enzyme variants, and breast cancer: a risk model.

Crooke PS, Ritchie MD, Hachey DL, Dawling S, Roodi N, Parl FF.

Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1620-9.

6.
7.

Association of homozygous wild-type glutathione S-transferase M1 genotype with increased breast cancer risk.

Roodi N, Dupont WD, Moore JH, Parl FF.

Cancer Res. 2004 Feb 15;64(4):1233-6.

8.
9.

Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1.

Dawling S, Roodi N, Parl FF.

Cancer Res. 2003 Jun 15;63(12):3127-32.

10.
11.

Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer.

Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH.

Am J Hum Genet. 2001 Jul;69(1):138-47. Epub 2001 Jun 11.

12.
13.

Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer.

Bailey LR, Roodi N, Dupont WD, Parl FF.

Cancer Res. 1998 Nov 15;58(22):5038-41. Erratum in: Cancer Res 1999 Mar 15;59(6):1388.

14.

Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans.

Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF.

Cancer Res. 1998 Jan 1;58(1):65-70.

15.

High-mobility group (HMG) protein HMG-1 and TATA-binding protein-associated factor TAF(II)30 affect estrogen receptor-mediated transcriptional activation.

Verrier CS, Roodi N, Yee CJ, Bailey LR, Jensen RA, Bustin M, Parl FF.

Mol Endocrinol. 1997 Jul;11(8):1009-19.

PMID:
9212049
16.

Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer.

Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD, Parl FF.

J Natl Cancer Inst. 1995 Mar 15;87(6):446-51.

PMID:
7861463
17.

Microsatellite instability and loss of heterozygosity in breast cancer.

Yee CJ, Roodi N, Verrier CS, Parl FF.

Cancer Res. 1994 Apr 1;54(7):1641-4.

18.

Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems.

Patston PA, Roodi N, Schifferli JA, Bischoff R, Courtney M, Schapira M.

J Biol Chem. 1990 Jun 25;265(18):10786-91.

Supplemental Content

Support Center